SpartaLabs
0
SpartaLabs Research · June 17, 2026

BPC-157: Published Research

A bibliographic summary of peer-reviewed studies examining BPC-157 across gastrointestinal, musculoskeletal, vascular, and neurological research models. Educational reference.

bpc-157preclinical-researchmusculoskeletalgastrointestinalneuroscience

Introduction

The peer-reviewed literature on BPC-157 encompasses studies conducted over more than three decades, spanning cell culture systems, rodent models, and early-phase human investigations. The compound, a stable 15-amino acid synthetic peptide derived from a partial gastric juice sequence, has been examined across a wide range of biological contexts. This article provides a bibliographic summary of representative peer-reviewed studies organized by research domain. All described findings were generated in preclinical (animal or cell culture) models unless otherwise noted. Readers seeking a background on BPC-157's chemical identity and pharmacological classification should consult the BPC-157 research overview.

Methodology Types in the Literature

The BPC-157 research literature encompasses several experimental methodologies. The most prevalent approach is the rodent (predominantly rat) injury or disease model, in which the compound is administered to animals with induced lesions and compared against vehicle or active control groups. Outcome measures in these models typically include histology, immunohistochemistry, behavioral scoring, and biomechanical testing.

Cell culture studies have examined BPC-157's effects on isolated fibroblasts, endothelial cells, and enteric neurons, reporting outcomes such as proliferation assays, migration assays, and receptor phosphorylation via Western blotting. A smaller body of work addresses pharmacokinetic parameters using radiolabeled compound in rats and dogs. Early-phase human studies were conducted by the Croatian pharmaceutical company Pliva during the 2000s and 2010s.

A 2025 systematic review published in HSS Journal by Vasireddi and colleagues applied systematic review methodology to the orthopaedic and sports medicine subset of this literature and identified the evidence base as consistent in preclinical direction across tissue types and model systems [1].

Summary of Studies by Domain

Gastrointestinal and Cytoprotective Research

The earliest and largest body of BPC-157 research addresses gastrointestinal tissue and cytoprotection. The foundational 1993 publication by Sikirić and colleagues in Journal of Physiology, Paris introduced BPC-157 as a partial sequence derived from a gastric protein and described preliminary observations in rodent gastric lesion models [2]. Subsequent studies from the same group documented observations in models of reflux esophagitis, cysteamine-induced duodenal lesions, short bowel syndrome, and NSAID-related gastrointestinal lesions.

A 2004 study in Digestive Diseases and Sciences by Sikirić and colleagues examined BPC-157 in a rat indomethacin-induced gastric ulcer model, reporting differences in mucosal lesion scoring between treated and untreated animals [3]. A 2007 study in the Journal of Pharmacological Sciences examined BPC-157 in a rat ileoileal anastomosis model in the context of inflammatory bowel disease research, reporting differences in anastomotic healing parameters in treated animals [4]. These preclinical studies accompanied early-phase human clinical investigations under the Pliva program designations PL-10, PLD-116, and PL14736.

A 2025 narrative review in Inflammopharmacology described the cytoprotective literature in aggregate, noting that BPC-157 had been examined in multiple gastrointestinal lesion models and that the most consistent observation across studies was attenuation of lesion formation or differences in tissue repair metrics in treated versus untreated rodent groups [5].

Musculoskeletal Research

A substantial number of studies have examined BPC-157 in tendon, ligament, muscle, and bone injury models. A 2006 study published in the Journal of Orthopaedic Research by Staresinic and colleagues examined BPC-157 in a rat Achilles tendon detachment model, reporting histological differences between treated and control animals at defined post-procedure time points [6].

A 2011 study in the Journal of Applied Physiology by Chang and colleagues investigated BPC-157's effects on tendon fibroblast cell biology in vitro, reporting that BPC-157 was associated with differences in fibroblast outgrowth, cell survival under stress conditions, and directional migration in scratch-wound assays — with the observations proposed to be mediated by changes in FAK and paxillin phosphorylation [7]. The molecular basis of these fibroblast observations is reviewed in the BPC-157 mechanism of action article. A follow-up study by the same group in 2014 reported growth hormone receptor upregulation among the most substantially altered genes in BPC-157-treated fibroblasts assessed by microarray analysis [8].

A 2025 narrative review in Current Reviews in Musculoskeletal Medicine by Lulofs and colleagues evaluated the musculoskeletal research literature and described the animal model findings as demonstrating "robust" preclinical observations across tissue types, identifying human randomized controlled trials as the next investigational priority [9]. A 2025 systematic review in HSS Journal by Vasireddi and colleagues surveyed the orthopaedic-specific literature and identified findings across fracture, tendon, ligament, muscle, and cartilage animal models, with preclinical findings generally consistent in direction [1].

Vascular and Cardiovascular Research

Published studies have examined BPC-157 in various vascular injury and ischemia models. A 2020 study in Scientific Reports by Hsieh and colleagues investigated BPC-157's effects on vascular tone in an isolated rat aorta preparation and in cultured endothelial cells, reporting NO-dependent vasomotor effects and activation of the Src-Cav-1-eNOS signaling cascade [10]. A related body of work from the Sikirić group examined BPC-157 in rodent models of major vessel occlusion and ischemia-reperfusion injury, with a 2022 publication reporting observations across Pringle maneuver and Budd-Chiari syndrome experimental preparations in rats [11].

A 2022 study in Biomolecules applied Fourier transform infrared (FTIR) spectroscopy to blood vessel tissue from BPC-157-treated rats, reporting molecular-level changes in protein secondary structure and lipid composition compared with controls [12]. The authors interpreted these findings as consistent with altered vascular tissue composition in treated animals.

Neurological and Behavioral Research

Published studies have examined BPC-157 in rodent models of CNS pathology, dopaminergic disruption, and gut-brain axis investigation. A 2022 review article in Neural Regeneration Research by Sikirić and colleagues summarized CNS-directed animal model observations, including reports of effects in rodent stroke models, traumatic brain injury models, and models of neuroleptic-induced behavioral abnormalities [13]. Reported observations included differences in neuronal damage histology markers and behavioral scoring in treated versus untreated animals.

A 2016 paper in Current Neuropharmacology by Sikirić and colleagues examined the brain-gut axis framing for BPC-157 research, describing animal model observations across gastrointestinal and neurological domains and proposing a shared mechanistic framework involving NO and dopaminergic signaling [14]. The 2025 literature review by Józwiak and colleagues noted that the neurotransmitter-directed research was predominantly rodent-based, with clinical investigation in neurological contexts representing a forward research priority [15].

Pharmacokinetic Studies

A 2022 pharmacokinetic study published in Frontiers in Pharmacology by He and colleagues conducted systematic characterization of BPC-157 absorption, distribution, metabolism, and excretion in rats and beagle dogs using LC-MS/MS analytical methods [16]. The study reported rapid metabolism to smaller peptide fragments and amino acids, and tissue distribution across multiple organ compartments — consistent with conventional peptide metabolic behavior. This characterization established the pharmacokinetic foundation for subsequent PK-PD modeling work linking systemic exposures to observed tissue-level effects.

Active Research Frontier

The BPC-157 research literature has grown to encompass several hundred peer-reviewed publications across gastrointestinal, musculoskeletal, vascular, and neurological domains. Key directions identified by the most recent literature assessments include: formal PK-PD integration linking systemic exposures to observed tissue-level effects, independent replication of core preclinical findings, and advancement to randomized controlled human investigation where preclinical evidence is most consistent. The 2025 systematic review by Vasireddi and colleagues characterized the current evidence base as a productive preclinical foundation and called for well-designed human trials as the field's next priority [1]. Another regenerative peptide with an overlapping musculoskeletal and vascular research corpus is TB-500, which has similarly been examined in tendon and wound-healing animal models. Researchers sourcing BPC-157 for laboratory investigation will find purity verification details on the BPC-157 product page.

References

  1. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. PMID: 40756949. DOI: 10.1177/15563316251355551. https://pubmed.ncbi.nlm.nih.gov/40756949/

  2. Sikirić P, Petek M, Rucman R, Seiwerth S, Grabarević Z, Rotkvić I, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313–327. PMID: 8298609. https://pubmed.ncbi.nlm.nih.gov/8298609/

  3. Sikirić P, Seiwerth S, Rucman R, Grabarević Z, Petek M, Jagić V, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. Dig Dis Sci. 2004;49(11–12):1897–1904. PMID: 15052688. https://pubmed.ncbi.nlm.nih.gov/15052688/

  4. Sikirić P, Seiwerth S, Grabarević Z, Rucman R, Petek M, Jagić V, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. J Pharmacol Sci. 2007;104(1):7–17. PMID: 17713731. https://pubmed.ncbi.nlm.nih.gov/17713731/

  5. Sikirić P, Krezić I, Zizek H, Smoday IM, Sikirić S. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT). Inflammopharmacology. 2025. PMC12396989. https://pmc.ncbi.nlm.nih.gov/articles/PMC12396989/

  6. Staresinic M, Petrovic I, Novinscak T, Jukic I, Pevec D, Suknaic S, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982–989. PMID: 16583442. DOI: 10.1002/jor.20112. https://pubmed.ncbi.nlm.nih.gov/16583442/

  7. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. PMID: 21030672. DOI: 10.1152/japplphysiol.00945.2010. https://pubmed.ncbi.nlm.nih.gov/21030672/

  8. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–77. PMC6271067. DOI: 10.3390/molecules191119066. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/

  9. Lulofs R, Spaans M, Kokshoorn NE. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025. PMID: 40789979. https://pubmed.ncbi.nlm.nih.gov/40789979/

  10. Hsieh MJ, Lee CH, Chueh HY, Ho TY, Lin CY, Chen KB, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. PMID: 33051481. DOI: 10.1038/s41598-020-74064-0. https://pubmed.ncbi.nlm.nih.gov/33051481/

  11. Sikirić P, Seiwerth S, Rucman R, Staresinic M, Sikiric S, Brcic L, et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World J Gastroenterol. 2022;28(2):222–236. PMC8793015. https://pmc.ncbi.nlm.nih.gov/articles/PMC8793015/

  12. Grabarević Z, Seiwerth S, Batelja L, Blagaić V, Tvrdeić A, Sosa I, et al. Fourier transform infrared spectroscopy reveals molecular changes in blood vessels of rats treated with pentadecapeptide BPC 157. Biomolecules. 2022;12(12):1730. PMC9775416. https://pmc.ncbi.nlm.nih.gov/articles/PMC9775416/

  13. Sikirić P, Seiwerth S, Rucman R, Staresinic M, Sikiric S, Brcic L, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482–487. PMC8504390. DOI: 10.4103/1673-5374.320969. https://pmc.ncbi.nlm.nih.gov/articles/PMC8504390/

  14. Sikirić P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Brain-gut Axis and Pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857–865. PMID: 27138887. DOI: 10.2174/1570159X13666160502153022. https://pubmed.ncbi.nlm.nih.gov/27138887/

  15. Józwiak P, Lipiec K, Maleszka A, Krześlak A. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals. 2025;18(2):185. PMID: 40005999. DOI: 10.3390/ph18020185. https://pubmed.ncbi.nlm.nih.gov/40005999/

  16. He Y, Chang R, Han B, Shi C, Li Y, Wang H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1086885. PMC9794587. https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/

Frequently asked questions

  • What research has been done on BPC-157?

    The peer-reviewed literature on BPC-157 encompasses several hundred publications spanning more than three decades. Studies have been conducted across gastrointestinal, musculoskeletal, vascular, and neurological model systems using cell culture, rodent injury models, and early-phase human investigations. A 2025 systematic review in HSS Journal by Vasireddi and colleagues described the preclinical evidence base as consistent in broad direction across tissue types.

  • Are there clinical trials for BPC-157?

    Early-phase human clinical investigations of BPC-157 formulations were conducted by the Croatian pharmaceutical company Pliva during the 2000s and 2010s, focusing primarily on inflammatory bowel disease and wound healing. These investigations established a preliminary human safety profile referenced in subsequent preclinical publications. No pivotal Phase III trials have been identified in publicly accessible regulatory databases as of the preparation of this article.

  • What did musculoskeletal BPC-157 studies find?

    Published musculoskeletal studies have examined BPC-157 in tendon, ligament, muscle, and bone injury models. A 2006 study in the Journal of Orthopaedic Research reported histological differences in a rat Achilles tendon detachment model. A 2011 study in the Journal of Applied Physiology reported differences in fibroblast outgrowth, cell survival under stress, and directional migration in BPC-157-treated cells compared with controls. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine described the animal model findings as demonstrating robust preclinical observations across tissue types.

  • What pharmacokinetic data exists for BPC-157?

    A 2022 pharmacokinetic study published in Frontiers in Pharmacology by He and colleagues conducted systematic characterization of BPC-157 absorption, distribution, metabolism, and excretion in rats and beagle dogs using LC-MS/MS analytical methods. The study reported rapid metabolism to smaller peptide fragments and amino acids, and tissue distribution across multiple organ compartments — consistent with conventional peptide metabolic behavior.